A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
Nat Commun
; 11(1): 4081, 2020 08 14.
Article
in English
| MEDLINE | ID: covidwho-717117
ABSTRACT
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Nat Commun
Journal subject:
Biology
/
Science
Year:
2020
Document Type:
Article
Affiliation country:
S41467-020-17972-1
Similar
MEDLINE
...
LILACS
LIS